Literature DB >> 27878344

Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy.

Yizhi Xiao1, Hui Luo1, Bin Zhou1, Xiaodan Dai1, Jing Huang1, Liping Duan1, Yunhui You1, Weiru Zhang1, Hongjun Zhao1, Yanli Xie1, Yaou Zhou1, Wangbin Ning1, Tong Li1, Sijia Liu1, Honglin Zhu1, Xiaoyun Xie1, Ying Jiang1, Shiyao Wu1, Weijia He1, Yisha Li2.   

Abstract

The aim of the study was to measure the diagnostic values of biomarkers of bacterial infection in idiopathic inflammatory myopathy (IIM) patients. The serum and clinical data of 82 IIM patients with/without bacterial infection were collected. Concentrations of soluble urokinase plasminogen activator receptor (suPAR), soluble triggering receptor expressed on myeloid cells 1 (sTREM-1), procalcitonin (PCT) and C-reactive protein (CRP) were measured in IIM patients and healthy controls. There were no significant differences in serum suPAR and sTREM-1 levels between healthy controls and non-infection IIM patients. Serum levels of suPAR, sTREM-1, PCT and CRP measured in this study were significantly higher in the IIM patient group with concurrent infection than in the non-infection IIM patient group (p < 0.05). The biomarker suPAR showed the highest diagnostic value with sensitivity, specificity, positive predictive value and negative predictive value of 81.6, 77.3, 75.6 and 82.9%, respectively. Combining suPAR negative and CRP negative to rule out bacterial infection in IIM patients provides a very high specificity of 97.4%. Both suPAR and CRP positive to confirm bacterial infection give the specificity of 90.9%. The inflammatory biomarkers suPAR, sTREM-1, PCT and CRP offer diagnostic accuracy in detecting bacterial infection in IIM patients. Particularly, suPAR is the most sensitive and specific biomarker to predict bacterial infection in IIM patients. Combination of suPAR and CRP serum levels provides an even better confirmation of bacterial infection.

Entities:  

Keywords:  Idiopathic inflammatory myopathy; Infection; Soluble triggering receptor expressed in myeloid cells 1; Soluble urokinase plasminogen activator receptor

Mesh:

Substances:

Year:  2016        PMID: 27878344     DOI: 10.1007/s00296-016-3609-x

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  40 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis.

Authors:  Athina Savva; Maria Raftogiannis; Fotini Baziaka; Christina Routsi; Anastasia Antonopoulou; Pantelis Koutoukas; Thomas Tsaganos; Anastasia Kotanidou; Efterpi Apostolidou; Evangelos J Giamarellos-Bourboulis; George Dimopoulos
Journal:  J Infect       Date:  2011-08-03       Impact factor: 6.072

3.  Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan.

Authors:  Daniel E Furst; Anthony A Amato; Şerban R Iorga; Kavita Gajria; Ancilla W Fernandes
Journal:  Muscle Nerve       Date:  2012-05       Impact factor: 3.217

Review 4.  Serum procalcitonin in systemic autoimmune diseases--where are we now?

Authors:  Irina Buhaescu; Robert A Yood; Hassan Izzedine
Journal:  Semin Arthritis Rheum       Date:  2010-02-04       Impact factor: 5.532

5.  Release of the soluble urokinase-type plasminogen activator receptor (suPAR) by activated neutrophils in rheumatoid arthritis.

Authors:  Boris K Pliyev; Mikhail Yu Menshikov
Journal:  Inflammation       Date:  2010-02       Impact factor: 4.092

6.  Value of soluble TREM-1, procalcitonin, and C-reactive protein serum levels as biomarkers for detecting bacteremia among sepsis patients with new fever in intensive care units: a prospective cohort study.

Authors:  Longxiang Su; Bingchao Han; Changting Liu; Liling Liang; Zhaoxu Jiang; Jie Deng; Peng Yan; Yanhong Jia; Dan Feng; Lixin Xie
Journal:  BMC Infect Dis       Date:  2012-07-18       Impact factor: 3.090

7.  Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.

Authors:  Alexander Koch; Sebastian Voigt; Carsten Kruschinski; Edouard Sanson; Hanna Dückers; Andreas Horn; Eray Yagmur; Henning Zimmermann; Christian Trautwein; Frank Tacke
Journal:  Crit Care       Date:  2011-02-16       Impact factor: 9.097

Review 8.  Clinical review: role of triggering receptor expressed on myeloid cells-1 during sepsis.

Authors:  Sébastien Gibot
Journal:  Crit Care       Date:  2005-06-03       Impact factor: 9.097

9.  High Level Serum Procalcitonin Associated Gouty Arthritis Susceptibility: From a Southern Chinese Han Population.

Authors:  Wen Liu; Keshav Raj Sigdel; Ying Wang; Qun Su; Yan Huang; Yan Lin Zhang; Jie Chen; Lihua Duan; Guixiu Shi
Journal:  PLoS One       Date:  2015-07-16       Impact factor: 3.240

10.  Biomarkers of sepsis.

Authors:  Sung-Yeon Cho; Jung-Hyun Choi
Journal:  Infect Chemother       Date:  2014-03-21
View more
  2 in total

1.  Patients with anti-Jo1 antibodies display a characteristic IgG Fc-glycan profile which is further enhanced in anti-Jo1 autoantibodies.

Authors:  Cátia Fernandes-Cerqueira; Nuria Renard; Antonella Notarnicola; Edvard Wigren; Susanne Gräslund; Roman A Zubarev; Ingrid E Lundberg; Susanna L Lundström
Journal:  Sci Rep       Date:  2018-12-18       Impact factor: 4.379

2.  Hsp90 Levels in Idiopathic Inflammatory Myopathies and Their Association With Muscle Involvement and Disease Activity: A Cross-Sectional and Longitudinal Study.

Authors:  Hana Štorkánová; Sabína Oreská; Maja Špiritović; Barbora Heřmánková; Kristýna Bubová; Olga Kryštůfková; Heřman Mann; Martin Komarc; Kryštof Slabý; Karel Pavelka; Ladislav Šenolt; Josef Zámečník; Jiří Vencovský; Michal Tomčík
Journal:  Front Immunol       Date:  2022-01-28       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.